Serna Bio is an AI-enabled, drug discovery company developing small molecules that modulate translation and splicing for validated, challenging-to-drug targets to treat diseases with high unmet medical need. At Serna Bio, we operate at the convergence of synthetic biology, machine learning (ML), and massively multiplex screening to tackle the fundamental challenges of drugging the transcriptome.
Using a combination of in vitro assays and machine learning tools, we have developed a unique understanding of RNA architecture, defining druggable, functional RNA motifs by mapping structure, function and context, transcriptome-wide. We have established the world’s largest database of functional RNA structures and unique, function-first chemical libraries, powering both internal programs and external collaborations.
